Podcasts about isth

In the latest episode of our advocacy series on The Association Insights Podcast (previously The Association 100 podcast - same great content, fresh new name!), host Colleen Gallagher engages in a compelling conversation with Louise St. Germain, Director of Membership, Marketing, and External Relations at theInternational Society on Thrombosis and Haemostasis (ISTH). With over 24 years of experience in membership, marketing, and external relations, including 12 years at the ISTH, Louise shares her journey and the impactful work of the society.Key Highlights:Career Path and Early Experiences: Louise reflects on her diverse background, starting with her role at the American Red Cross during Hurricane Katrina, where she learned the importance of flexibility, resourcefulness, and building relationships. These experiences laid the foundation for her subsequent work in communications and PR for non profits and associations.The Power of Partnerships: Emphasizing that "nothing happens alone," Louise discusses the critical role of partnerships in advancing ISTH's mission. Collaborations with entities like the World Health Organization and the European Thrombosis and Haemostasis Alliance have been pivotal in extending the society's reach and impact.World Thrombosis Day Campaign: Louise dives into the success of the World Thrombosis Day campaign, an initiative she describes as akin to nurturing a child now in its 12th year. The campaign has significantly increased global awareness of blood clot risks, influenced healthcare policies, and fostered collaborations with numerous organizations and governments worldwide.Advocacy and External Relations: Louise outlines the ISTH's multi-pronged approach to advocacy, which leverages scientific evidence, expert voices, and patient stories. Engaging early and often with regulatory bodies like the FDA and EMA, and aligning with broader public health priorities, has been central to their strategy.Crisis Communication and Preparedness: Drawing from her early experiences, Louise highlights the importance of proactive crisis communication planning. She advocates for developing clear, living crisis communication response plans and bringing teams along in preparedness efforts to maintain public trust during challenging times.Adapting to Policy Changes: In light of recent changes in the U.S. administration, Louise discusses how ISTH remains agile by monitoring global policy shifts and aligning their messaging with evolving healthcare priorities. Positioning ISTH as a nonpartisan, evidence-based organization has been key to effectively engaging with policymakers.Future Trends in Advocacy and Public Affairs: Looking ahead, Louise identifies key trends such as the integration of AI and digital strategies, personalized engagement, and cross-sector collaboration. She emphasizes the importance of associations staying relevant by embracing these trends and continually innovating in their approaches.Join us for this insightful discussion as Louise St. Germain shares her experiences and strategies in association management, marketing, and advocacy, offering valuable takeaways for professionals in the field.Stay Connected:Subscribe to The Association 100 podcast onSpotify,Apple Podcasts orYouTube Podcasts to ensure you never miss an episode.Follow us on LinkedIn atOnWrd & UpWrd for the latest in association trends and strategies.Tune in next week as we continue our advocacy series with another insightful discussion to help associations navigate the evolving political landscape.

Mit 170 von 184 gültigen Stimmen ist Maja Riniker heute zur Nationalratspräsidentin gewählt worden - damit gilt sie für die nächsten 12 Monate als höchste Schweizerin. Nach der Wahl wandte sich die 46-Jährige FDP-Politikerin an ihre Familie. Zudem plädierte sie für Vielfalt, die unser Land ausmache. Die weiteren Themen dieser Sendung: · Freispruch für einen Hirnchirurgen, der an der Hirslanden-Klinik operiert hat. Er habe seine Sorgfaltspflicht nicht verletzt. 2018 ist eine seiner Patientinnen nach einer Operation verstorben. · Weniger Kosten für den Kanton Solothurn wegen assistierten Suiziden bei der Sterbehilfeorganisation Pegasos in Nunningen: Die Staatsanaltschaft untersucht die Todesfälle künftig anhand von Videoaufnahmen, die Pegasos zur Verfügung stellt. · Bei der Druckerei Vogt-Schild in Derendingen/SO werden pro Jahr vier Mal 6 Millionen Abstimmungsbüchlein gedruckt. Die Reportage dazu.

Häuslicher Gewalt zu entrinnen, ist ein langer und steiniger Weg. Warum es für Bäuerinnen ganz besonders schwierig ist ihren gewalttätigen Partner zu verlassen, darüber spricht Katrin Gottardi vom Frauenhausdienst Brixen.

Professorin Domino erklärt- ob man Ameisen als Haustiere halten kann- ob häufiger Schluckauf ein Zeichen dafür ist, dass man wächst

In Georgien demonstrieren Tausende gegen das offizielle Ergebnis der Wahl. Dieses anzuerkennen, wäre wie einen Einmarsch Russlands zu akzeptieren, sagt die Präsidentin. Der Kulturkampf von Großkriminellen gegen die Demokratie ist auf einem Höhepunkt. Franke, Thomas www.deutschlandfunk.de, Kommentare und Themen der Woche

This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and... The post Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges appeared first on VJHemOnc.

In dieser Folge erzählen wir unsere Urlaubserlebnisse und die Dinge die in den letzten drei Wochen passiert sind.

Die transformative Kraft von BIM sowie BIC mit fortschrittlichen KI-Algorithmen – mit diesen Themen und ihren Unternehmen thinkBIC sowie BIM GLW hat sich Dr. Lisa Lenz fest in der Baubranche etabliert. Wie genau ihre Arbeit die digitale Zukunft der Baubranche allgemein vorantreibt, erfährst du in dieser Podcastfolge. Moderation: Kaita Ronn, CSO und Mitgründerin der TOPEOPLE GROUP.

Warum sind „Michael Schmidt“ und „Sabine Müller“ in unseren Fallvignetten so häufig? Und was haben Identitäten eigentlich mit Krankheitsbildern zu tun? Ring frei für ein Meta-Thema!

This episode of CLOT Conversations features Dr Sam Schulman (Hamilton) and Dr Michelle Sholzberg (Toronto) discussing the 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19 of which they were two of the co-authors.While COVID-19 is no longer considered a global emergency, healthcare professionals continue to see critical and non-critical cases regularly. This is particularly the case in locations where medical care is challenging.There was a need to update the 2022 guidelines due to the large number of recently-published studies in the area that were not included in the 2022 edition. Consideration was given to recommendations that could be implemented globally. This is an important update to take into account when encountering patients with sever COVID illness.Reference:Schulman S, Arnold DM, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH, Middeldorp S, Minichiello T. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. Journal of thrombosis and haemostasis. 2024 Mar 18.Support the Show.https://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Die Frauen haben am Montagabend nach einem souveränen Heimsieg das Ticket für Europa gelöst und Rang drei gesichert. Der Cheftrainer Niko Arnautis spricht über eine anspruchsvolle Saison, berichtet im Podcast über Einschlafschwierigkeiten nach Abendspielen und warum die Eintracht Frauen dieses Jahr den nächsten Entwicklungsschritt gemacht haben. Aber das war noch nicht alles: Natürlich lässt Niko Arnautis noch etwas Liebe für die beiden Eintracht-Legenden Sebastian Rode & Makoto Hasebe da.

Jeden Montag und Donnerstag Kult: SWR3-Moderator Kristian Thees ruft seine beste Freundin Anke Engelke an und die beiden erzählen sich gegenseitig ihre kleinen Geschichtchen des Tages.

Hannes kann es: https://www.instagram.com/hanneskannes_schulspeaker/ rock.it.raketenstarter@gmail.com www.hanneskannes-schulspeaker.de Musik lizensiert durch audiohub

Wir podcasten heute von einer Dachterrasse in Athen und haben gleich zwei neue Segmente: In "Top oder Flop" bewerten wir europäische Städte (mit einem Augenzwinkern!). In "Was hätte ich sagen sollen?" lesen wir eine schreckliche Dating-Story vor und überlegen, was man in dieser Situation hätte sagen können. Habt ihr auch eine Situation, in der ihr nicht wusstet, was ihr sagen sollt? Schickt uns eine (Audio-)Nachricht! Hinweis: Die Episode am 16.4. fällt reisebedingt aus. Unsere nächste Episode erscheint am 20.4.2024.   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsoren Hier findet ihr unsere Sponsoren und exklusive Angebote: easygerman.org/sponsors   Top oder Flop: Europäische Städte Honest Guide (YouTube-Kanal) Copenhagenize Index (Wikipedia) Platzangst in Barcelona (Easy German Podcast 290)   Outro WORTE WIE REGEN - Poesie von Marit Persiel (Crowdfunding unserer Jingle-Sprecherin Marit auf Startnext)   Wichtige Vokabeln in dieser Episode die Dachterrasse: ein Außenbereich, der sich auf dem Dach eines Gebäudes befindet, oft mit Sitzgelegenheiten und Pflanzen lebenswert: beschreibt einen Ort oder eine Situation, die angenehm, erfüllend und gut zum Leben ist der Geheimtipp: eine Empfehlung oder ein Ratschlag, der nicht allgemein bekannt ist die Erwartung: das Gefühl oder die Vorstellung, dass etwas Bestimmtes passieren wird oder sollte jemanden abholen (ugs): jemanden verstehen oder auf emotionaler Ebene erreichen die Lokalrivalität: Wettbewerb oder Feindseligkeit zwischen zwei Gruppen, Teams oder Unternehmen aus dem gleichen geografischen Gebiet stammeln: Sprechen mit Schwierigkeiten oder Unterbrechungen, oft aufgrund von Nervosität oder Aufregung etwas schildern: beschreiben oder erzählen von etwas in einer detaillierten oder anschaulichen Weise   Support Easy German and get interactive transcripts, live vocabulary and bonus content: easygerman.org/membership

Das Streben nach Höchstleistungen ist für viele Unternehmen ein erstrebenswertes Ziel. Für besondere Aufgabenstellungen kann der Einsatz von High Performance Teams dabei unterstützen. Doch was zeichnet High Performance Teams aus und wie baut man sie auf? In welchen Situationen macht ihr Einsatz Sinn und wie steuert man sie? Und wie kann man High Performance Teams für Höchstleistung im Controlling nutzen? Darüber spreche ich mit  Prof. Dr. Ulrike Baumöl und Thomas Bolli  in einem zweiteiligen Podcast. Thomas Bolli blickt auf eine über vierzigjährige Berufslaufbahn als Militär- und Linienpilot zurück. Außerdem übte er verschiedene Managementfunktionen aus, etwa als Flottenchef Airbus bei Swissair und als CEO des SWISS-eigenen Trainingsunternehmens SWISS-Aviation-Training. Prof. Dr. Ulrike Baumöl von der Universität St. Gallen beschäftigt sich unter anderem intensiv mit den Themen Business Engineering und Change Management – zwei Themenfelder, die gerade in einer rasant sich verändernden Arbeitswelt und gleichzeitig immer komplexer werdenden Geschäftsmodellen hochaktuell sind.

Das Streben nach Höchstleistungen ist für viele Unternehmen ein erstrebenswertes Ziel. Für besondere Aufgabenstellungen kann der Einsatz von High Performance Teams dabei unterstützen. Doch was zeichnet High Performance Teams aus und wie baut man sie auf? In welchen Situationen macht ihr Einsatz Sinn und wie steuert man sie? Und wie kann man High Performance Teams für Höchstleistung im Controlling nutzen? Darüber spreche ich mit  Prof. Dr. Ulrike Baumöl und Thomas Bolli  in einem zweiteiligen Podcast.  Thomas Bolli blickt auf eine über vierzigjährige Berufslaufbahn als Militär- und Linienpilot zurück. Außerdem übte er verschiedene Managementfunktionen aus, etwa als Flottenchef Airbus bei Swissair und als CEO des SWISS-eigenen Trainingsunternehmens SWISS-Aviation-Training. Prof. Dr. Ulrike Baumöl von der Universität St. Gallen beschäftigt sich unter anderem intensiv mit den Themen Business Engineering und Change Management – zwei Themenfelder, die gerade in einer rasant sich verändernden Arbeitswelt und gleichzeitig immer komplexer werdenden Geschäftsmodellen hochaktuell sind. Der zweite Teil wird ab dem 28.03.2024 veröffentlicht.

The world of association management is evolving, and Thomas Reiser, the executive director of the International Society on Thrombosis and Hemostasis, is at the forefront of this. Reiser sat down with Skift Meetings to share his insights on what is shaping the future of associations and events in a post-Covid-pandemic landscape. "The traditional membership value is diminishing," Reiser candidly reveals, pointing to the challenges facing associations worldwide. This captures the seismic shifts that have prompted organizations like ISTH to reassess and retool their value propositions to members. This episode covers: Reiser's varied and international career spans multiple association management roles, including his current role. He has implemented major shifts, including shifting from a biennial to an annual congress and insourcing almost all event-related roles. We discuss the importance of the real role of medical societies, which is ultimately to improve people's lives We delve into the importance of public-facing initiatives such as World Kidney Day and World Thrombosis Day, both of which Tom was involved in launching. How Tom and ISTH work with suppliers as consultants and true partners And finally we look at the key trends that Tom sees as the biggest challenges and opportunities. Head to www.skiftmeetings.com to explore our daily news coverage and free-to-access reports and events.

Franziska Hentke weiß,worauf es ankommt. Als ehemalige Profischwimmerin kann sie auf ca. 40 Höhentrainingslager zurückblicken, was einem Aufenthalt in der Höhe von knapp 1 1/2 Jahren entspricht. Und hier verrät sie ihre Tipps! Auch diese Folge ist wieder ein Special des ESCAPE-Netzwerks und bietet eine Übersicht zu praktischen Erfahrungen und medizinischen Aspekten des Höhentrainings. Um Athlet:innen, Trainer:innen, Mediziner:innen uvm. über diese Thematik aufzuklären und sie diskussionsfähig zu machen, findet sich in Episode #023 der dritte Teil unserer Trilogie zum Thema "Höhentraining". Bevor man sich Part III widmet, empfehlen wir, die ersten beiden Teile zu hören: Part I - Was passiert in der Höhe? (Episode #019) Part II - (Wie) Wirkt Höhentraining? (Episode #020) In Part III widmen wir uns verschiedenen Fragen, die vor allem auf die konkrete Umsetzung eines Höhentrainingslagers abzielen: - Wie bereitet man sich im Vorfeld vor? - Was ist im Bezug auf Eisen zu beachten? - Wie ist ein Höhentrainingslager aufgebaut? - Wie läuft das Monitoring in der Höhe? - Warum ist die Ernährung besonders wichtig? UND: - Welche Tipps haben Expert:innen für uns? Als Experten im Gespräch sind in dieser Folge Dr. med. Andreas Kästner und Utz Brenner aus dem ESCAPE-Netzwerk. Andreas ist Kardiologe und hat schon viele Profisportler:innen im Kontext von Höhentrainingslagern betreut. Utz trainiert seit Jahren einige Profiathlet:innen und greift dabei auch auf Höhentraining zurück. Darüber hinaus haben wir im Vorfeld zu diesem Austausch tolle O-Töne und Fragen über SpeakPipe zugeschickt bekommen. Neben der ehemaligen Profischwimmerin Franziska Hentke haben wir euch einige Erfahrungen von Hannes Vitense einfangen können, der als langjähriger Bundestrainer im Deutschen Schwimmverband tätig ist. Ihr wollt wissen wer noch dabei ist und was wir machen? Hier geht's zur E.S.C.A.P.E. Homepage. Für Anmerkungen, Fragen und weitere Themenvorschläge - schickt mir gerne eine Sprachnachricht über SpeakPipe. Andreas' socials: Instagram Website Utz auf Instagram Meine "Socials": Instagram YouTube ResearchGate Literatur: 1) Koivisto-Mørk et al. (2020) Front Sports Act Living 2) Michalczyk et al. (2016) nutrients 3) Stellingwerff et al. (2019) Sports Med Kapitel: 0:00:00 Teaser 0:01:00 Intro 0:03:42 Speed Meet 0:07:01 Vorstellung Dr. Andreas Kästner 0:11:18 Vorstellung Utz Brenner 0:12:57 ESCAPE-Netzwerk (Part I & II) 0:14:51 Ist Höhentraining etwas für jeden? 0:20:18 Welchen Umfang trainiert man? 0:27:13 Wie sieht es mit Intensitäten aus? 0:33:00 Erfahrungswerte sammeln hilft 0:36:38 Wie bereite ich das Höhentraining vor? 0:41:55 Exkurs Eisenstoffwechsel 0:46:16 Eisenwerte in der Praxis 0:50:10 Wie baut man ein Höhentraining auf? 0:57:40 Monitoring im Höhentrainingslager 1:03:45 Wie ernährt man sich in der Höhe? 1:15:23 Wie sollte man Eisen supplementieren? 1:20:14 Ernährungsfehler vermeiden 1:23:00 Schlechte Erfahrungen im Höhentraining 1:26:15 Wann ist der beste Zeitpunkt? 1:35:57 Tipps von den ESCAPE-Experten 1:42:04 Tipps vom Deutschen Schwimmverband 1:43:49 Outro

Häufiges ist häufig - Typische Themen in der Kinderosteopathie Willkommen zurück zu Auftriebskraft, dem Podcast, der dir hilft, alternative Wege zu einem gesunden Lebensstil zu erkunden. Heute werden wir über ein Thema sprechen, das viele Eltern betrifft: die häufigsten Gesundheitsprobleme bei Kindern und wie die Osteopathie eine unterstützende Rolle spielen kann.   Listen on:   Stefanrieth.com: Apple:  https://podcasts.apple.com/de/podcast/auftriebskraft/id1331666188 Stitcher; https://www.stitcher.com/show/dynamic-stillness-der-osteopathie-podcast Spotify: https://open.spotify.com/show/6rNJUxu71iwKobqdagKiOq?si=150dd16e6eea4aab   Dein Stefan Rieth, Msc. Ost., D.O.   --- Ausschluss von Heilungsversprechen Bitte beachten Sie, dass es sich bei der Osteopathie um nicht wissenschaftlich und/oder schulmedizinisch anerkannte und/oder bewiesene Verfahren handelt und die Wirksamkeit wissenschaftlich und/oder schulmedizinisch nicht anerkannt ist. Besonderer Hinweis zum HWG (Heilmittelwerbegesetz) Aus rechtlichen Gründen weise ich besonders darauf hin, das bei keinem der aufgeführten Therapien- oder Diagnoseverfahren der Eindruck erweckt wird , das hier ein Heilungsversprechen meinerseits zugrunde liegt, bzw. Linderung oder Verbesserung einer Erkrankung garantiert oder versprochen wird. Sollte der Inhalt oder die Aufmachung dieser Seiten fremde Rechte Dritter oder gesetzliche Bestimmungen verletzen, so bitte ich um eine entsprechend kostenfreie Nachricht. Ich werde die zu Recht beanstandeten Passagen unverzüglich entfernen, ohne dass die Einschaltung eines Rechtsbeistandes erforderlich ist. Etwaig ohne vorherige Kontaktaufnahme ausgelöste Kosten jedweder Art werden insgesamt zurückgewiesen. Abmahnungen Keine Abmahnung ohne vorherigen Kontakt. Sollte der Inhalt der Aufmachung meiner Seiten fremde Rechte Dritter oder gesetzliche Bestimmungen verletzen, so bitte ich um eine entsprechende Nachricht ohne Kostennote. Ich garantiere, dass die zu Recht beanstandeten Textpassagen unverzüglich entfernt werde, ohne dass von Ihrer Seite die Einschaltung eines Rechtsbeistandes erforderlich ist. Ferner werde ich von Ihnen ohne vorherige Kontaktaufnahme ausgelösten Kosten vollumfänglich zurückweisen und gegebenenfalls Gegenklage wegen Verletzung vorgenannter Bestimmungen einreichen. Ziel dieses Hinweises ist keine Abmahnung z.B. formlose E-Mail) zu erhalten, sondern nicht mit den Kosten einer anwaltlichen Abmahnung belastet zu werden. Es ist nicht vertretbar, in einem solchen Falle die Notwendigkeit einer anwaltlichen Abmahnung zu bejahen.            

Die deutschen Unternehmen blicken im Februar leicht optimistischer in die Zukunft. Außerdem: Börsenexperte Ulf Sommer erklärt, was Anleger über dividendenstarke Aktien und die Besteuerung von ETFs und Fonds wissen sollten.

Die Armee durchläuft schwierige Zeiten. Ausgerechnet jetzt, wo Expertinnen und Experten die globale Sicherheitslage als labil einschätzen. Wie ist der Zustand der Schweizer Armee? Und der Zustand der Welt? Georg Häsler ist NZZ-Militärexperte. Die Schweizer Armee muss bekanntlich Rüstungskäufe für insgesamt 1.4 Milliarden Franken verschieben. Armeechef Süssli warnt gleichzeitig vor einem Verlust des Heers. Wie dramatisch ist die Situation? Ausserdem: Heute treffen sich in Brüssel die Nato Verteidigungsministerinnen und Minister. Denn der Ukraine geht schlicht die Munition aus. Gibt sich die Nato angesichts des verheerenden und raschen Negativtrends einen Ruck und liefert mehr? Das alles unter dem Eindruck der momentanen geopolitischen Lage: Die Welt bewegt sich, so das Londoner Strategieinstitut IISS, auf ein gefährliches Jahrzehnt zu. Die Sicherheitslage ist höchst labil. Einschätzungen von Georg Häsler, Journalist bei der NZZ, Sicherheits- und Militärexperte und Oberst im Heeresstab der Armee.

Koppitz, Sonjawww.deutschlandfunkkultur.de, Plus Eins

Das ewige Streben nach MEHR Immer höher, immer schneller, immer weiter... Wann ist denn eigentlich genug? Haben wir je genug? Nach diesem Motto habe ich die letzten Jahre gelebt. Wie es dazu kam und wie ich jetzt darüber danke erfahrt ihr heute in einer ganz persönlichen Folge. Wir sollten uns oft hinterfragen WARUM ist das so? Sind das wirklich meine Wünsche nach mehr? Mehr Urlaub, mehr Wohlstand, mehr ja was eigentlich? Taucht heute mit mir ein in die Welt von Porsche, Champagner, Chanel und hinterfragt euer warum. --- Send in a voice message: https://podcasters.spotify.com/pod/show/elina-heinze3/message

Böttcher, Martin /Schmidt, Anne-Sophiewww.deutschlandfunkkultur.de, Echtzeit

Raya Petke macht heute einen auf Quizmaster und testet euer Schulwissen! Geschichte, Mathe, Erdkunde - was habt ihr (noch) drauf? Raya fordert euch in unterschiedlichen Fächern heraus: Level "Beginner" bis "Pro"! Danach ist Storytime: Wie war die Schulzeit für euch? Was haltet ihr vom Schulsystem? Habt ihr noch Kontakt zu Freund:innen oder hattet ihr vielleicht sogar mit Mobbing zu tun? Oder: Wie geht es euch gerade in der Schule?

CME credits: 1.50 Valid until: 11-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/meaningfulness-of-isth-chart-audit-of-in-hospital-mortality-for-ich/14741/ The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

CME credits: 1.50 Valid until: 11-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/meaningfulness-of-isth-chart-audit-of-in-hospital-mortality-for-gi-bleeds/14738/ The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

CME credits: 1.50 Valid until: 11-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/newest-emerging-data-from-isth-andexanet-alfa-vs-4f-pcc/14737/ The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

 Dr Vicky Mai presented multiple times at the ISTH 2023. Dr Le Gal talks to her about the research that she presented and the implications. The first study that she presented was a systematic review with metaanalysis on thrombolysis in intermediate high and high risk PE. The second one was an abstract on a sub analysis of the PREDICTORS study which looked at the risk of recurrent VTE in patient who presented with a suspicion of recurrent VTE on anticagulation. And there's two projects on COPD exacerbation and pulmonary embolism. Join us on Twitter:@thrombosiscan@VickyMai@grelegalVisit www.thrombosiscanada.ca for more information and resourcesSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Dr Abdulrehman interviews three researchers working in Canada who presented work at ISTH 2023 in Montreal. Dr Menal Huroy, reviews her poster on The Impact of GI Surgeries on peak plasma anti-Xa Direct Oral Anticoagulant levels, Dr Adam Suleman discusses his research on The Risk iof VTE in Primary CNS Lymphoma: A Systematic Review and Dr Ismail Raslan discussed his research, Anticoagulation Post-Pulmonary Endarterectomy: A Retrospective Cohort Study. Three quick interviews covered in 11 minutes!Follow us on Twitter:@thrombosiscanSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this interview, two of the authors of the paper Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials, Dr Jean Connors and Dr Benhood Bikdeli, provide listeners with an overview of their systematic review and meta-analysis that evaluated the efficacy and safety of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in patients with thrombotic antiphospholipid syndrome. The authors searched through three databases (PubMed, EMBASE, and Cochrane Central Register of Controlled Trials) and found four eligible randomized controlled trials with a total of 472 patients. Our podcast guests discuss the results of the study and the clinical implications.  About our guests:Dr Jean M Connors: Jean M. Connors, MD is a hematology attending at Brigham and Women's Hospital and Dana-Farber Cancer Institute; the Medical Director of the Anticoagulation Management Services, and the Hemostatic Antithrombotic Stewardship Program; and an Associate Professor of Medicine at Harvard Medical School. She received a medical degree from The Johns Hopkins University in Baltimore, completed her residency in internal medicine at Beth Israel Deaconess Medical Center in Boson, as well as fellowships in transfusion medicine and hematology & oncology from Brigham and Women's Hospital.Dr. Connors is an Associate Editor for the Journal of Thrombosis and Haemostasis and the Journal of the American College of Cardiology: Basic to Translational Science. She is a member of or holds a leadership role in many professional societies, including ASH and ISTH. She has participated in numerous clinical trials for patients with venous thrombosis in cancer, and anticoagulation questions in general.Dr Benhood Bikdeli:Behnood Bikdeli, MD, MS is a clinician-investigator, with training in cardiology and in vascular medicine who is particularly interested in thrombotic diseases. He is an Associate Physician in the Division of Cardiovascular Medicine at Brigham and Women's Hospital, an Instructor in Medicine at Harvard Medical School, and an investigator at Yale Center for Outcomes Research and Evaluation (CORE). His research has been funded by the NIH, the American Heart Association, Brigham and Women's Hospital and others. Dr Bikdeli has coauthored over 180 publications, which have been published in journals including Lancet, JAMA, JAMA Internal Medicine, Circulation, Journal of the American College of Cardiology, the British Medical Journal, and others. Dr. Bikdeli was the lead author of two international consensus documents related to thrombosis in COVID-19, is the joint principal investigator of the INSPIRATION/ INSPIRATION-S randomized controlled trial, and is an Associate Editor for Thrombosis Research. Ref:Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., ... & Bikdeli, B. (2022). Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials. Journal of the American College of Cardiology.Follow us on Twitter:@thrombosiscan@connors_mdSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we interview two of the authors of a recent paper, Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH, Dr Maha Othman and Dr Leonardo Brandao on this paper from the Journal of Thrombosis and Haemostasis. 2022;20:1735–1743. Severe congenital protein C deficiency (SCPCD) is rare and there is currently substantial variation in the management of this condition. A joint project by three Scientific and Standardization Committees of the ISTH was developed to review the current evidence and help guide on diagnosis and management of SCPCD.About our guests:Dr. Maha Othman is a clinical pathologist/hematologist with specialized training in haemostasis laboratory testing and molecular genetics of bleeding disorders. She obtained her medical degree and MSc in Clinical Pathology in Mansoura University in Egypt. She then completed her PhD in Pathology from Southampton University, UK. After this, she pursued post-doctoral research training in molecular genetics of hemophilia and von Willebrand disease with Dr. David Lillicrap, at Queen's University, Canada. Dr. Othman is currently a full Professor at the School of Medicine, Queen's University and at St Lawrence College, Kingston, Ontario. Her research interests include the clinical and molecular aspects of von Willebrand disease and platelet disorders particularly PT-VWD, and thromboelastography assessment of coagulopathies in women, pregnancy and cancer. She has more than 100 research papers and her research is recognized internationally. She is an editor for Seminars in Thrombosis and Haemostasis and Research and Practice in Thrombosis and Haemostasis Journals. She is a reviewer for a number of Haemostasis journals and a member of several scientific organizing committees on women's health, and advisory boards for international haemostasis conferences. She is the previous Chairman of the Scientific and Standardization Committee (SSC) on Women's Health Issues in Thrombosis and Haemostasis of the ISTH and currently CO-Chair on the SSC for DIC. She is a passionate educator and mentor and an advocate for rare bleeding disorders and bleeding and clotting disorders in women.Dr. Leonardo Brandão  is a native Brazilian who joined the staff at The Hospital for Sick Children in 2004. Since 2019, he has been the Thrombosis Program director. He obtained his medical degree at the University of São Paulo (USP) School of Medicine (FMUSP) before moving to North America, where he completed his post-graduate training (Paediatrics Residency at Emory University, Atlanta/GA, Paediatric Haematology/Oncology fellowship at St. Jude Children's Research Hospital, Memphis/TN, and a second fellowship in Paediatric Coagulation at Weill Cornell University, New York/NY). After finishing his training, he moved to Canada to focus on the field of paediatric thrombosis at SickKids. He is the past-chair of the thrombosis committee for the Canadian Pediatric Thrombosis Hemostasis Network (CPTHN), past-Canadian representative-elect for the Hemostasis and Thrombosis Research Society (HTRS), past-member of the first paediatric venous thromboembolism panel for the American Society of Hematology (ASH), past-co-chair of the paediatric thrombosis subcommittee for the International Society on Thrombosis and Hemostasis (ISTH), and a member of Thrombosis Canada. Links:Thrombosis Canada Clinical Guide:Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Wie viele Bücher von Männern werden veröffentlicht und wie viele von Frauen? Die Autorin Nicole Seifert hat nachgezählt. Ergebnis: Das Verhältnis bessert sich zwar – aber da ist noch Luft nach oben.Nicole Seifert im Gespräch mit Joachim Schollwww.deutschlandfunkkultur.de, LesartDirekter Link zur Audiodatei

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In this series of our new season we will be covering Womens' health and looking at the broader implications of coagulation and then speaking to a Lupus patient advocate on the impact this disease has had for her personally. To start off, in today episode, we are delighted to speak to our Clinical Development Director, Dr Francois Depasse about the broader connection between Womens' Health and coagulation and then a more in depth look at APS. Links to related podcasts: S1E13 - Lupus anticoagulant diagnosis work-up https://www.podcastics.com/podcast/episode/13-the-lupus-anticoagulant-diagnosis-work-up-54015/ S3E7 - Hemostasis results interpretation along pregnancy https://www.podcastics.com/podcast/episode/s3e7-hemostasis-results-interpretation-along-pregnancy-134753/ Literature sources: https://www.cdc.gov/ncbddd/blooddisorders/women/facts.html Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306 Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 809-813 CLSI Laboratory testing for the Lupus anticoagulant - Approved Guideline. CLSI document H60-A. Wayne, PA; 2014. Devreese, KMJ, de Groot, PG, de Laat, B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18: 2828– 2839. https://doi.org/10.1111/jth.15047    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Viele beim Weltnaturgipfel COP15 bewerten das Artenschutzabkommen als historisch. Doch es stellt nicht alle zufrieden. „Viele der 23 Ziele sind so schwammig wie auftauender Permafrostboden“, meint SWR-Umweltredakteur Axel Weiß in seinem Kommentar.

This week, please join author Sean Pokorney and Associate Editor Shinya Goto as they discuss the article "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial." Dr Carolyn Lam:               Welcome to Circulation on the Run, your weekly podcast summary and Backstage Pass of the journal and its editors. We're your cohost. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley:            And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Carolyn, this week's feature, very interesting topic. In patients that have end stage renal disease that require dialysis, questions emerged should we anticoagulate them to prevent stroke, but of course, there's a risk of excess bleeding. Well, this feature discussion today is a study comparing apixaban and warfarin for anticoagulation in exactly this patient population. But before we get to those results, how about we grab a cup of coffee and go through some of the other articles in the issue? Would you like to go first? Dr Carolyn Lam:               Absolutely, Greg. So my first paper is a pre-specified analysis of the Paradise MI trial and knowing you'll likely ask me what that was about, Greg, at least to summarize for everyone, the Paradise MI trial compared sacubitril/valsartan with ramipril and its effect on reducing heart failure events after an MI in more than 5,600 patients with an acute myocardial infarction complicated by LV systolic dysfunction, pulmonary congestion, or both. Now in today's paper, what Dr. Mehran and colleagues found was that among patients with a recent AMI and LV systolic dysfunction, heart failure are both, sacubitril/valsartan decreased the risk of coronary related events by 14% as compared with ramipril over a median follow-up of 22 months. The reduction in coronary events occurred with a favorable safety profile. Dr Greg Hundley:            Wow, Carolyn, very interesting. Another indication perhaps for sacubitril/valsartan, especially relative to ACE inhibitors. So what does this mean for us clinically? Dr Carolyn Lam:               Well, the results really cause us to consider if in addition to antiplatelets and lipid lowering therapies, sacubitril/valsartan may be explored as a potential agent to mitigate the residual risk in survivors of AMI. Of course, dedicated studies are necessary to confirm this finding and elucidate its mechanism. Dr Greg Hundley:            Oh, very nice, Carolyn. Well, my first paper comes to us from the World of Preclinical Science and Carolyn, this study evaluated the scavenger receptors stabilin-1 and stabilin-2, proteins that are preferentially expressed by liver sinusoidal endothelial cells. Now, they mediate the clearance of circulating plasma molecules controlling distant organ homeostasis. And studies suggest that stabilin-1 and stabilin-2 may impact atherosclerosis. So in this study, the investigative team led by Professor Cyrill Géraud from the University Medical Center and Medical Faculty in Mannheim, Heidelberg comprehensively studied how targeting stabilin-1 and stabilin-2 affects atherosclerosis. Dr Carolyn Lam:               Huh. All right, nicely explained. And so what did they find, Greg? Dr Greg Hundley:            Right, Carolyn. So inhibition of evolutionary conserved class H scavenger receptors, stabilin-1 and stabilin-2, reduced aortic plaque burden in preclinical models and athero protection was mediated likely through down regulation on transcriptional factor ERG1 in monocytes by multifaceted plasma protein changes. And then finally, Carolyn transforming growth factor beta induced periostin, reelin, and they are novel ligands of stabilin-1 and stabilin-2 and are implicated in the development of atherosclerosis. Dr Carolyn Lam:               Okay. Wow. Could you give us a take home message, please Greg? Dr Greg Hundley:            Right. Carolyn, I knew you had asked me this. So here we go. Monoclonal, anti-stabilin-1 and anti-stabilin-2 antibodies provide a novel approach for the future treatment of atherosclerosis. And in the future, perhaps the plasma proteome composition may serve as a predictive factor, biomarker or surrogate parameter for cardiovascular disease in patients. Dr Carolyn Lam:               Wow. Thanks Greg. My next paper is a true story of discovery. Now I could ask you what you know about the condition hypertension with brachydactyly type E... Greg, I love that expression. I wouldn't be able to answer that too. So let me tell you the story. So hypertension with brachydactyly type E is an autosomal dominant Mendelian disease resembling essential hypertension. Untreated patients die of stroke by the age of 50 years. Now, these authors had previously demonstrated a gain of function phosphodiesterase 3A gene mutations that caused the condition by increasing peripheral vascular resistance. They studied a large family with the condition earlier and were puzzled that cardiac hypertrophy and heart failure did not occur despite the decades of hypertension. And so they hypothesized that in the heart, this phosphodiesterase 3A or PDE3A mutations could be protective. Isn't that neat? And so corresponding authors, Doctors Bader, Klussmann, Bähring and Hübner, all from the Max Delbruck Center for Molecular Medicine in Berlin, Germany. So they studied new patients as well as CRISPR-Cas9 engineered rat models of this condition of hypertension with brachydactyly type E. And they comprehensively phenotyped all of them with the human induced pluripotent stem cells carrying these PDE3A mutations as well. So analyzing all of this from cells to new patients to CRISPR-Cas9 models. Dr Greg Hundley:            Wow, Carolyn, what an interesting story. So what did they find? Dr Carolyn Lam:               So while in vascular smooth muscle, the PDE3A mutations caused hypertension, in the hearts, they conferred protection against hypertension-induced cardiac damage, hypertrophy and heart failure. The mechanism involved long-term adaptations of mRNA and protein expression as well as calcium cycling. Non-selective PDE3A inhibition was a final short term option in heart failure treatment to increase cardiac cyclic AMP and improve contractility. So the data argued that mimicking the effect of PDE3A mutations in the heart rather than non-selective PDE3 inhibition was cardioprotective in the long term. And these findings could indeed facilitate the search for new treatments to prevent hypertension-induced cardiac damage. This is discussed in a really lovely editorial by Dr. Chiong, Houslay, and Lavandero. Dr Greg Hundley:            Very nice, Carolyn. Wow. What another... we have such great articles from the World of Preclinical Science. Beautiful description as well. Well, we have some other articles in the issue, particularly from the Mailbag. And we have a Research Letter from Professor Thiagarajan entitled “Yield of Cardiac MRI in a pre-participation cohort of Young Asian males with T-Wave inversion.” Dr Carolyn Lam:               Interesting. There's an exchange of letters between Dr. Xu and Huang regarding the article associations of dietary cholesterol, serum cholesterol and egg consumption with overall and cause-specific mortality with a systematic review and updated meta-analysis. There is a Perspective piece by Dr. Marcus on Smart watch detected atrial fibrillation, the value in positive predictive value. Isn't that interesting? And now onto that very, very important question of anticoagulation in patients with kidney disease. Can't wait. Let's go, shall we? Dr Greg Hundley:            You bet. Carolyn. Welcome listeners to our December 6th feature discussion. And we have with us today Dr. Sean Pokorney from Duke University in Durham, North Carolina, and our associate editor, Dr. Shinya Goto from Tokai University in Isehara, Japan. Welcome gentlemen. Well, Sean, we're going to start with you. Can you describe for us some of the background information that went into the preparation of your study and what was the hypothesis that you wanted to address? Dr. Sean Pokorney:         Yeah, absolutely. Thanks for having me to discuss the renal AF trial. And so I would say that the background information to the study was that we know that atrial fibrillation is an incredibly common condition in patients with chronic kidney disease. And the decision of anticoagulation in patients with end-stage kidney disease, on hemodialysis is really quite complex because these patients are at high risk for stroke and they're at high risk for bleeding. There are concerns with warfarin around calcific uremic arteriolopathy or calciphylaxis and there have been some data including from the original Aristotle trial that apixaban was even more favorable in terms of bleeding reduction relative to warfarin in patients with more advanced chronic kidney disease. Although patients with creatinine clearance less than 25 were excluded from Aristotle and really all patients with endstage kidney disease on hemodialysis have been excluded from all trials of atrial fibrillation in the past. And so we really wanted to evaluate the safety of apixaban versus warfarin in patients with end-stage kidney disease, on hemodialysis. And the hypothesis was that apixaban was going to be non-inferior to warfarin with respect to safety in terms of major or clinically relevant, non-major bleeding in these patients with atrial fibrillation and end stage kidney disease on hemodialysis. Dr Greg Hundley:            Thanks so much, Sean. And you've mentioned the renal AF trial. So could you describe for us, for your, I guess, substudy, what was the study population? Who did you include and describe for us also your study design? Dr. Sean Pokorney:         Yeah, absolutely. So the trial included patients who had end-stage kidney disease, and/or on hemodialysis, as well as having concomitant atrial fibrillation. And the patients had to have a CHA-VASc score greater than equal to two. All of the patients had to be on hemodialysis for at least three months. So these were chronic hemodialysis patients. And the study design was an open label randomized trial that was 1:1 randomization between apixaban and warfarin with blinded outcome evaluation. And again, the primary endpoint of the study was major or clinically relevant non-major bleeding based on ISTH definitions. And there were secondary endpoints looking at stroke, systemic embolism, death, medication adherence, and I think a really important sub-study looking at PK data. And the goal was to have 50 patients where we included PK data that was going to more represent what chronic apixaban dosing data would look like in these patients with end-stage kidney disease on hemodialysis. And originally the goal of the trial was to include over 700 patients. Originally we were trying to include 762 patients based on our initial power calculations to achieve true non-inferiority. Unfortunately, the trial enrollment was low and so the trial was ultimately stopped prematurely at 154 patients, although we were able to include the original targeted 50 patients in the PK substudy. The dosing that we used in the renal AF trial was 5 mg of apixaban twice daily unless patients had a second dose-reduction criteria in addition to chronic kidney disease. So the fact that they had end-stage kidney disease and were on hemodialysis counted as one dose reduction criteria and patients that were under 60 kilograms or less were 80 years of age or older, who had then a second dose-reduction criteria were treated with the 2.5 mg twice daily dosage. And this was important to note because this is different than the dosage that was used in the AXADIA-AFNET trial. Dr Greg Hundley:            Very nice. And so Sean, what did you find? Dr. Sean Pokorney:         Yeah. So again, a lot of this data is really exploratory because of the limited sample size, we weren't really able to definitively conclude anything about the major or clinically relevant non-major bleeding rates. I would say that some of the key findings that we saw was that there were high rates of major or clinically relevant non-major bleeding in both arms of the trial and one year bleeding event rates were 25% in the warfarin arm and 31% in the apixaban arm. And again, there was no statistically significant difference, although again, this is really exploratory. I would say that some of the other interesting findings that we saw was that there were very low rates of ischemic and hemorrhagic stroke in this patient population. Again, there were 82 patients randomized to apixaban, 72 patients randomized to warfarin. And there was a difference in the randomization because of the stratification by site that was performed with the randomization. And so within the 82 patients that were randomized to apixaban, the patients, there was one ischemic stroke and one hemorrhagic stroke. There were no hemorrhagic strokes in the warfarin population and two ischemic strokes. Another key finding was the high rates of mortality in this patient population. So 26% of the apixaban patients experienced a mortality event, 18% in the warfarin arm. So again, the mortality rates in these patient populations were extremely high. I would also emphasize some of the data from the PK analysis. So we looked at the PK analysis in two different ways. For the patients that were treated with the 5 mg dose of apixaban, the PK data showed that there was consistent overlap in the steady state concentration at one month compared to patients in the Aristotle trial that had really mild to moderate, moderate to severe and severe chronic kidney disease. And so there was a consistent overlap in those steady state concentrations between the end-stage kidney disease population on hemodialysis and the chronic kidney disease population who benefited from a apixaban in the Aristotle trial. Similarly, in the 2.5 mg apixaban dose, the patient who had a second dose reduction criteria in addition to chronic kidney disease, those patients had consistent steady state concentrations of apixaban relative to patients with mild to severe chronic kidney disease. Dr Greg Hundley:            Very nice. Well thank you so much, Sean. And listeners, now we're going to turn to our associate editor, Dr. Shinya Goto. Shinya, can you, sort of, highlight for us some of the interesting findings that you see from these study results that Sean just presented? Dr. Shinya Goto:              Thank you, Greg. Thank you, Sean for your wonderful summary of your study. We had a great discussion with an editor for this paper. As Sean pointed out, this is a kind of underpowered trial or just terminated early, hypothesis was not tested in the trial. But this population of patient clearly needs a real-world clinical trial, patient with atrial fibrillation, end-stage kidney disease, on hemodialysis; things a clinician could do. In some country, nephology society defined warfarin contraindicated in this population. As Sean pointed out, whether the development of this trial include this high-risk population patient. So we had a discussion whether the underpowered trial provided something or nothing may be better than something just provided here. Our consensus finally reached was, this limited trial still provide something like, you have to make a decision to use the anticoagulation. I mean, that the apixaban might be still used due to the PK data. That is the kind of interesting point of this trial. Dr Greg Hundley:            Very nice Shinya. Well, Sean, turning back to you and Shinya with that nice lead in really, Sean, what do you think is the next study that needs to be performed in this sphere of research? Dr. Sean Pokorney:         Yeah, absolutely. I think this is a challenging patient population to study. And again, our trial, the renal AF trial stopped early. Unfortunately, the AXADIA-AFNET 8 study also stopped early, which was also looking at apixaban versus warfarin outside the US and Europe. And so again, it is a challenging patient population to study. But again, I also think it's a really important population to study because one of the main unanswered questions in this population is whether or not they should receive anticoagulation. And so I think that ultimately more work and additional studies trying to determine whether or not these patients truly benefit from anticoagulation or stroke prevention, I think is really one of the critical directions that we need to take the field in. Dr Greg Hundley:            And Shinya, do you have anything to add? Dr. Shinya Goto:              Well, I fully agree with Sean. I mean, this is a very challenging area and still raising the question whether anticoagulation is necessary or not by your study. Maybe next generation oral anticoagulant such as Factor XI inhibitor that is more elevated to contact pathway may be beneficial. So we really need a good clinical study in this very important and known answered area. Dr Greg Hundley:            Very nice. Well listeners, we want to thank Dr. Dr. Sean Pokorney from Duke University in Durham, North Carolina and our own associate editor, Dr. Shinya Goto from Tokai University in Japan for bringing us the results of this randomized open-label trial of apixaban versus warfarin in patients with chronic kidney disease on hemodialysis, revealing high rates of bleeding in both groups, but due to low enrollment, was unable to identify its non-inferiority endpoint. It's important to note, however, as both our author and editorialists have identified further research is really needed in this area to really examine the efficacy of anticoagulation for stroke prevention in this high-risk patient population. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week On The Run. Dr. Greg Hundley:           This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Römer

Römer

大家有注意到這集 „Kaffeeklatsch mit Bianca“ 換了新的開場音樂嗎？ ⁡ 這集的來賓—Peggy，就是幫我們量身打造歌曲的Hummingbird團員之一喔！ ⁡ Peggy不僅在她熱愛的音樂領域中綻放才華，目前也正在德國參與Volkswagen軟體工程師培訓計畫，更是當年計畫中唯一錄取的台灣人喔！ ⁡ 讓我們來聽聽她美妙的歌聲，以及勇敢追尋夢想的故事！ ⁡ ——— 【節目摘要】 1. 因為歌唱活動而相識，德語劈啪聊全新開場音樂的創作者－Peggy來節目上囉！(01:45) 2. 勇敢作夢，不為自己設限！抓緊機會前往德國BTU！(05:04) 3. 透過許多方式控管生活預算，在德國讀書一年花費不到20萬台幣？(08:50) 4. 學習語言沒有捷徑－「慢慢來比較快」，重點是要找到適合自己的學習方式！(13:29) 5. 希望未來能在德國工作：爭取實習接觸前端App，進而喜歡IT工作，開啟新的契機 (28:00) 6. 成功挑戰「福斯集團軟體工程師全德文培訓計畫」，成為5%的入取者，唯一的台灣人 (31:48) 7. 文化衝擊：原來德國人也會害怕說英文？毛毛蟲符號是什麼？「已讀不回」是常態！(39:44) 8. 在德國有很多„Young Tarif“，你有記得去使用嗎？(48:15) 9. 積極參與音樂交流活動，「Hummingbird－蜂鳥」在德國傳遞台灣音樂花粉 (51:08) 10. 德國音樂風格：Double time rap、經典的Schlager；甚至有很多意想不到的台灣歌曲是來自德語翻唱？(58:29) 11. Peggy實踐著：「世界有多大，取決於自己的心胸有多大」，„Wie groß die Welt ist, hängt davon ab, wie groß dein Herz ist.“ (1:04:53) ⁡ ——— ▲更多內容記得到「德語劈啪聊」的網站 Web→ deutschpipapo.com/ IG→ www.instagram.com/deutschpipapo/ ⁡ ↓↓↓ ▲了解更多Hummingbird： 【Hummingbird｜IG】https://bit.ly/3Ukeria 【青春，台南 My life, Tainan】https://bit.ly/3fp5NQx 【做十六 Turning sixte】https://bit.ly/3TVIGfb

Women, girls, and those with the potential to menstruate (WGPPM) who live with hemophilia, have more difficulty getting a diagnosis and accessing adequate care than their biological male counterparts. But why? What research is underway to support the needs of these individuals? This episode takes a wide-lens approach to exploring the socio-cultural barriers and gender-related challenges facing WGPPM in the global hemophilia community.   Contributors: Dawn Rotellini Andra James, MD, MPH Connie Miller, PhD Tyler Buckner, MD Maureen Baldwin, MD, MPH Kristin Paulyson Nunez, M.S., C.G.C   Senior Advisor: Donna DiMichele, MD   Episode Advisors: Angela Weyand, MD Robert Sidonio, MD   Hosted by: Laurence Woollard   Links to learn more: Bercovitz RS. “A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH”: Comment. J  Thromb Haemost 2022;20(7):1744-45. DOI: 10.1111/jth.15727   Chaudhury A, et al. Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. Haemophilia 2021;27(2):293-304. DOI: 10.1111/hae.14232   d'Oiron R, et al. Women and girls with haemophilia: Lessons learned. Haemophilia 2021;27(S3):75-81. DOI: 10.1111/hae.14094   DiMichele DM, et al. Severe and moderate haemophilia A and B in US females. Haemophilia 2014;20(2):e136-43. DOI: 10.1111/hae.12364   Fox L. Women and girls with hemophilia: Gender-based differences in comprehensive care. NHF Bleeding Disorders Conference 2019. [Online]. Available at: https://www.hemophilia.org/research/research-projects/women-and-girls-with-hemophilia-gender-based-differences-in-comprehensive-care   Kirtava A, et al. Trends in clinical management of women with von Willebrand disease: A survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004;10:158-161. DOI: 10.1046/j.1351-8216.2003.00832.x    Malouin RA, et al. Practice Characteristics of Genetic Counselors Serving the North American Bleeding Disorders Community. [Poster]. World Federation of Hemophilia 2016 World Congress , May 2016.    Miller CH, et al. Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States. Haemophilia 2021;27(6):1037-44. DOI: 10.1111/hae.14403   Rajpurkar M, et al. Current challenges for men and women with mild-to-moderate haemophilia. Haemophilia 2021;27(S1):5-7. DOI: 10.1111/hae.14193   van Galen K, et al. European principles of care for women and girls with inherited bleeding disorders. Haemophilia 2021;27(5):837-47. DOI: 10.1111/hae.14379   van Galen KPM, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost 2021;19(8):1883-87. DOI: 10.1111/jth.15397   Weyand AC, James PD. Sexism in the management of bleeding disorders. Res Pract Thromb Haemost 2020;5(1):51-4. DOI: 10.1002/rth2.12468   Show Notes: Presenting Sponsor: Sanofi Subscribe to the Global Hemophilia Report   Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter  Listen to the FLOW podcast

Daniela mag Menschen und ihre Geschichten. Jede Geschichte ist hörenswert und anders. Als überzeugte Systemikerin liebt sie die systematischen Fragen, die dabei helfen können, andere Blickwinkel auf ein Problem zu eröffnen und neue Möglichkeiten und Handlungsoptionen zu schaffen. Ihren Beruf als Coach und Trainerin erlebt Daniela als sehr bereichernd und erlebt sich darin auch immer ein Stück weit als Lernende. Daniela ist selbst sehr wissbegierig und somit ist auch das Thema Schule und Lernen, eines ihrer Lieblingsthemen. Weitere Informationen zu Daniela Diosegi findest du hier: Homepage: www.d-coach.de Podcast: https://d-coach.de/podcast/ E-Mail: info@d-coach.de

This episode recorded at the ISTH2022 meeting in London features interviews with Dr Rita Selby and Dr James Douketis with Dr Jameel Abdulrehman. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Thrombosis Canada members Mark Crowther and Taylor Drury join host Jameel Abdulrehman in a discussion on some highlights from the 2022 ISTH meeting in London. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Thrombosis Canada members Jameel Abdulrehman, Tsu-Fei Wang, Marc Carrier, Joseph Shaw and Yan Xu discuss their highlights from day 2 of the ISTH 2022 program. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Seit Beginn der Corona-Pandemie stirbt die Veranstaltungsbranche einen langsamen, aber inzwischen in weiten Teilen kaum mehr aufzuhaltenden Tod. Verschiebungen, Absagen, der Wegfall von Veranstaltern und Veranstaltungsorten sind dabei nur eine Seite der Medaille. Auf der anderen Seite stehen Künstler, Agenten und meist freiberufliche Selbstständige im Technik- und Service-Bereich, die in den vergangenen zweieinhalb Jahren mitWeiterlesen

In der fünften Folge spricht Benedict Kleindienst mit Ivan Kitta, Head of Marketing bei "GoodMills Deutschland" darüber:Was man unter Nutzerversprechen versteht und wieso dies für jede Innovationen essentiell istWelche Faktoren Unternehmen bei der Definition des innovativen Nutzerversprechens beachten müssenWas bei der Positionierung und Vermarktung des innovativen Nutzerversprechen wichtig istHöre jetzt rein und folge unserem Kanal, um wöchentlich mehr darüber zu erfahren, wie auch du erfolgreich digital transformieren kannst.Mehr zu Ivan Kitte auf LinkedIn: https://www.linkedin.com/in/ivan-kitta-7a281b20/Wenn du mehr darüber erfahren möchtest, wie wir dich unterstützen können, dann schaue auch auf unserer Website vorbei:https://bit.ly/3EThEP3

In der vierten Folge spricht Benedict Kleindienst mit Patrick Haede, Product Leader bei Gorillas darüber:Weshalb es wichtig ist, frühzeitig sein Produkt mit Hypothesen zu validierenWelche Rolle Nutzerfeedback dabei spielt und wie du dies am besten erhältstAb welchem Zeitpunkt Prototyping sinnvoll istHöre jetzt rein und folge unserem Kanal, um wöchentlich mehr darüber zu erfahren, wie auch du erfolgreich digital transformieren kannst.Mehr zu Patrick Haede findest du hier: https://www.linkedin.com/in/patrickhaede/Wenn du mehr darüber erfahren möchtest, wie wir dich unterstützen können, dann schaue auch auf unserer Website vorbei:https://bit.ly/3OIgMkL

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today's episode, our guest David Courtois will explain further what is platelet aggregometry, how to measure it and in which indications it is useful.   Literature sources: Born GVR. Aggregation of blood platelets by adenosine disphosphate and its reversal. Nature 1962; 194: 927 – 929. O'Brien JR. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962; 15: 452-458. Caen JP, Michel H. Platelet shape change and aggregation. Nature 1972; 240 (5377): 148-149. Holmsen H. Platelet metabolism and activation Semin Hematol. 1985; 22 (3): 2 19-40. Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation in Methods in Hematology, Churchill Livingstone, New-York 1983; 8: 64-91. Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123 (2): 172-183. Hvas AM, Favaloro EJ. Platelet function analyzed by light transmission aggregometry. Methods Mol Biol 2017; 1646: 321-331. Christie DJ, Avari T, Carrington LR, Cohen E, DeBiase BA, Harrison P, Kickler TS, Kottke-Marchant K, Ledford-Kraemer M, Rand ML, Schmaier AH, McCabe White M. Platelet function testing by aggregometry: approved guidelines, H58-A. Clinical and Laboratory Standards Institute: Wayne, PA, USA 2008; 28 (31): 1-45. Frontroth, J.P.; Favaloro, E.J. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. Methods Mol. Biol. 2017, 1646, 473–494. Hayward CPM, Pai M, Liu Y, Moffat KA, Seecharan J, Weber KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorders assessments. J Throm Haemost 2009; 7 (4): 676-684 Cattaneo M., Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSCC of the ISTH. J. Thromb Haemost 2009; 7: 1029 Hayward CPM, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder J.L. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-963. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30-44 Dawood BB, Lowe GC, Lordkipanidze M, Bem D, Daly ME, Makris M, Mumford A, Wilde JT, Watson SP. Evaluation of participants with suspected heritable platelet function disorder including recommendation and validation of a streamlined agonist panel. Blood 2012; 120 (25): 5041-5049. Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao KA, Schmaier AH, Watson SP, Lussana F, Pugliano MT. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Throm Haemost 2013; 11: 1183-1189. Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am 2013; 27 (3): 585-611. Nurden AT, Nurden P. Inherited disorders of platelet function: selected updates. J Thromb Haemost 2015; 13 (Suppl 1): 2-9. Frelinger AL 3rd, Gachet C, Mumford AD, Noris P, Mezzano D, Harrison P, Gresele P. Laboratory monitoring P2Y12 inhibitors communication from the SSC of the ISTH. J Throm Haemost 2018; 16 (11): 2341-2346 Podda G, Scavone M, Femia EA, Cattaneo M. Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets 2018; 29 (7): 644-649. Hayward CPM, Moffat KA, Brunet J, Carlino SA, Plumhoff E, Meijer P, Zehnder JL. Update on diagnostic testing for platelet function disorders: What is pratical and useful? Int J Lab Hematol 2019; 41 (Suppl 1): 26-32 Gresele P, Orsini S, Noris P, Falcinelli E, Alleci MC, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontan P, Guglielmini G, Pecci A, BAT-VAL study investigators (57). Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. J Thromb Haemost 2020; 18 (3): 732:739. Rabbolini D, Connor D, Morel-Kopp MC, Donikian D, Kondo M, Chen W, Alessi MC, Stevenson W, Chen V, Joseph J, Brighton C, Ward C, Sydney Platelet Group. An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology 2020; 52 (2): 243-255.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.